Announcements Trials

Browse Landscape

Phase

Status

Completed 7 Terminated 2 Recruiting 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1 Lymphoid 1

Conditions

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2 Lymphoma, T-Cell 1 Lymphoma 1 Leukemia, Biphenotypic, Acute 1 Leukemia 1

Interventions

venetoclax 21 Cyclophosphamide 14 Cytarabine 12 Azacitidine 8 fludarabine 7 Dexamethasone 5 Daunorubicin 5 ruxolitinib 4 revumenib 4 Trimethoprim, Sulfamethoxazole Drug Combination 4 quizartinib 3 pirtobrutinib 3 gamma-Globulins 3 fludarabine phosphate 3 blinatumomab 3 Tacrolimus 3 Rituximab 3 Palliative Care 3 Inotuzumab Ozogamicin 3 Granulocyte Colony-Stimulating Factor 3 Decitabine 3 Ciprofloxacin 3 Blood Specimen Collection 3 zanubrutinib 2 ponatinib 2 pembrolizumab 2 ibrutinib 2 aldesleukin 2 acalabrutinib 2 Watchful Waiting 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Leukemia × nelarabine × Clear all

NCT07294677 2026-03-04

CAVALRY

University of Chicago

Phase 1/2 Recruiting

LymphoidOther hematologic neoplasm

Leukemia, Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡